Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

References

• European Medicines Agency. Final report on the adaptive pathways pilot. 2016. [cited 2017 Nov 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf
   Google Scholar
• Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European medicines agency: retrospective cohort study of drug approvals 2009-13. Bmj. 2017;359:j4530.
   PubMed Web of Science ®Google Scholar
• Jönsson B, Wilking N. The effect of cancer drug vintage on cancer survival and mortality. Ann Oncol. 2007;18(Suppl3):iii67–5.
   Google Scholar
• Blumenthal GD, Kluetz PG, Schneider J, et al. Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies. Oncologist. 2017;22(7):726–767.
   Web of Science ®Google Scholar
• Jönsson B. Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development. Mol Oncol. 2015;9(5):1025–1033.
   Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Anderson KC. The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–452.
   PubMed Web of Science ®Google Scholar
• Smith BD, DeZern AE, Bastian AW, et al. Meaningful endpoints for therapies approved for hematological malignancies. Cancer. 2017;123(10):1689–1694.
   Web of Science ®Google Scholar
• Thornton Snider J, Batt K, Wu Y, et al. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma. Am J Manag Care. 2017;23(10):e340–e346.
   Web of Science ®Google Scholar
• Institute for Quality and Efficiency in Healthcare (IQWiG). Report N17-02: Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma. Available from: https://www.iqwig.de/en/projects-results/projects/non-drug-interventions/n-projekte/n17-02-allogeneic-stem-cell-transplantation-in-aggressive-b-cell-non-hodgkin-lymphoma-and-in-t-cell-non-hodgkin-lymphoma.7810.html
   Google Scholar
• Aggarwal C, Borghaei H. Treatment paradigms for advanced non-small cell lung cancer at academic medical centers: involvement in clinical trial endpoint design. Oncologist. 2017;22(6):700–708.
   Web of Science ®Google Scholar
• Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US food and drug administration approvals. JAMA Intern Med. 2015;175(12):1992–1994.
   PubMed Web of Science ®Google Scholar
• Hasan B, Greillier L, Pallis A, et al. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European organisation for research and treatment of cancer lung cancer group studies and an independent study validation. Eur J Cancer. 2014;50(16):2771–2782.
   Web of Science ®Google Scholar
• Beauchemin C, Cooper D, Lapierre MÈ, et al. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer. Onco Targets Ther. 2014;7:1101–1110.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Foster NR, Renfro LA, Schild SE, et al. Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10(7):1099–1106.
   Web of Science ®Google Scholar
• Tan A, Porcher R, Crequit P, et al. Differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at ClinicalTrials.gov. J Clin Oncol. 2017;35(15):1686–1694.
   PubMed Web of Science ®Google Scholar
• Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care. 2014;30(3):312–324.
   PubMed Web of Science ®Google Scholar
• Fiteni F, Westeel V, Bonnetain F. Surrogate endpoints for overall survival in lung cancer trials: a review. Expert Rev Anticancer Ther. 2017;17(5):447–454.
   PubMed Web of Science ®Google Scholar
• Hellman MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42–e50.
   Web of Science ®Google Scholar
• Liu LY, Yu H, Bai JL, et al. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer. Asian Pac J Cancer Prev. 2015;16(3):1001–1006.
   Google Scholar
• Pfeiffer BM, Kulakova M, Hashim M, et al. Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer? J Clin Oncol. [ Abstract] 2018;36(Suppl 15):9082.
   Web of Science ®Google Scholar
• Brogan AP, DeMuro C, Barrett AM, et al. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017;23(2):125–134.
   Web of Science ®Google Scholar
• Hashem F, Merritt R. Supporting patients self-managing respiratory health: a qualitative study on the impact of the breathe easy voluntary group network. ERJ Open Res. 2018;4(1):pii:00076–2017.
   Google Scholar
• Moreira T. Understanding the role of patient organizations in health technology assessment. Health Expect. 2015;18(6):3349–3357.
   Web of Science ®Google Scholar
• Dilla T, Lizan L, Paz S, et al. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence. 2016;10:1–7.
   PubMed Web of Science ®Google Scholar
• Siddiqi A, Given CW, Given B, et al. Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer Care (Engl). 2009;18(1):84–96.
   PubMed Web of Science ®Google Scholar
• Bottomley A. The cancer patient and quality of life. Oncologist. 2002;7(2):120–125.
   PubMed Web of Science ®Google Scholar
• Solem CT, Kwon Y, Shah RM, et al. Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology. Expert Rev Pharmacoecon Outcomes Res. 2018;188(3):245–253.
   Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–2577.
   PubMed Web of Science ®Google Scholar
• Miquel-Cases A, Schouten PC, Steuten LM, et al. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treat Rev. 2017;52:117–127.
   PubMed Web of Science ®Google Scholar
• EMA (European Medicines Agency). Annual Report 2017, London UK, 2017
   Google Scholar
• Lage A, Crombet T. Control of advanced cancer: the road to chronicity. Int J Environ Res Public Health. 2011;8(3):683–697.
   Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171.
   PubMed Web of Science ®Google Scholar